Skip to content
    RGEN
    Earnings call· Dec 2025(Q4 FY25)

    REPLIGEN Q4 FY25 earnings call RGEN

    Feb 24, 2026 Source

    Executive summary

    Repligen Q4 FY25 — Robust Organic Growth and Margin Expansion

    Repligen concluded FY25 with strong organic growth and margin expansion, driven by portfolio diversity and strategic execution. The company issued prudent FY26 guidance, balancing a strengthening macro backdrop with near-term uncertainties around FDA policy and biopharma CapEx decisions, while prioritizing continued investment and M&A. Innovation and operational fitness remain key strategic pillars for future growth.

    Highlights

    5

    • Q4 revenue of $198 million, translating to 14% organic growth.

    • Full-year 2025 organic growth of 14%, exceeding the high end of initial guidance.

    • Proteins and Process Analytics grew over 30% in Q4, with Chromatography over 25%.

    • Adjusted operating margin expanded by 90 basis points to 13.8% in FY25 (240 bps excluding M&A and FX).

    • Cash and marketable securities reached $768 million, up $90 million sequentially.

    Concerns

    5

    • 2-point headwind from a gene therapy platform impacting 2026 organic revenue guidance.

    • CDMO Q4 revenue grew low single digits year-over-year due to a tough comparison.

    • Muted demand for capital equipment in 2025, though sales were flat year-over-year.

    • Tariff surcharges expected to have a slightly higher impact on revenue and margin in 2026 (50 bps headwind on gross margin).

    • Lower interest income of $2 million in Q4 FY25 due to declining interest rates.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $810 million to $840 million
    high materiality
    High
    Full-year 2026 Organic Revenue Growth
    9% to 13%
    high materiality
    High
    Full-year 2026 Adjusted Gross Margin
    53.6% to 54.1%
    high materiality
    High
    Full-year 2026 Adjusted Income from Operations
    $122 million to $130 million
    high materiality
    High
    Full-year 2026 Adjusted Operating Margin Expansion
    150 basis points
    high materiality
    High
    Full-year 2026 Adjusted Effective Tax Rate
    22% to 23%
    medium materiality
    High
    Full-year 2026 Adjusted Fully Diluted EPS
    $1.93 and $2.01
    high materiality
    High
    Full-year 2026 Filtration Revenue Growth
    Low double digits
    medium materiality
    High
    Full-year 2026 Chromatography Revenue Growth
    Low double digits
    medium materiality
    High
    Full-year 2026 Proteins Revenue Growth
    Low double digits
    medium materiality
    High
    Full-year 2026 Analytics Revenue Growth
    Greater than 20%
    medium materiality
    High
    Full-year 2026 Revenue Seasonality
    ~48% in the first half
    low materiality
    Medium
    Q1 2026 Revenue
    Low single digits sequential decline
    medium materiality
    High
    Full-year 2026 CapEx Spend
    Approximately 3% to 4% of 2026 revenue
    low materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    North America
    Q4 growth driven by Proteins, ATF, and Fluid Management. Full-year growth was approximately 16%.
    		—mid-teens——
    EMEA
    Q4 growth driven by Proteins, Chromatography, and Analytics. Full-year growth was approximately 16%.
    		—more than 20%——
    Asia Pacific
    Q4 growth driven by Chromatography and Analytics. Full-year growth was 19%.
    		—high teens——

    Operational metrics

    29
    Organic Non-COVID Revenue Growth
    16%
    FY25

    Exceeded the high end of initial 2025 guidance.

    Organic Revenue Growth
    14%
    FY25

    Exceeded the high end of initial 2025 guidance.

    Q4 Organic Revenue Growth
    14%
    Q4 FY25

    Excluding the impact of acquisitions and foreign exchange.

    Acquisition Contribution to Q4 Reported Growth
    approximately 1 point
    Q4 FY25

    Contributed to the 18% reported year-over-year increase.

    Foreign Exchange Contribution to Q4 Reported Growth
    2 points
    Q4 FY25

    Contributed to the 18% reported year-over-year increase.

    Adjusted Gross Margin
    52.4%170 bps expansion YoY
    Q4 FY25

    Year-over-year increase.

    Adjusted Gross Margin
    52.6%220 bps increase YoY
    FY25

    Full-year performance.

    Adjusted Operating Income
    $30 millionup 19% YoY reported, up about 25% excluding FX and M&A
    Q4 FY25

    Sequentially flat OpEx to Q3.

    Adjusted Operating Margin
    15%up 10 bps YoY reported, 140 bps expansion excluding M&A and FX
    Q4 FY25

    Reflects the impact of M&A and foreign currency.

    Adjusted Operating Income
    $102 millionup 24% YoY reported, up 35% excluding M&A and FX
    FY25

    Growth driven by a $68 million increase in gross profit, reduced by $49 million of increased OpEx.

    Adjusted Operating Margin
    13.8%up 90 bps YoY reported, 240 bps expansion excluding M&A and FX
    FY25

    30 basis points better than prior guidance. Driven primarily by volume leverage and price, mostly offset by dilution from recent M&A investments.

    Adjusted EBITDA Margin
    19%up 50 bps YoY reported, 230 bps excluding M&A and FX
    FY25

    Full-year performance.

    Adjusted Net Income
    $28 millionup $3 million YoY
    Q4 FY25

    Higher adjusted operating income was offset by $2 million of lower interest income on declining interest rates.

    Adjusted Effective Tax Rate
    20%
    Q4 FY25

    Slightly better than prior expectations due to tax planning actions.

    Adjusted Fully Diluted EPS
    $0.49vs $0.44 in Q4 FY24
    Q4 FY25

    Per share.

    Adjusted Fully Diluted EPS
    $1.71up 9% YoY
    FY25

    $0.03 better than the high end of October guidance.

    Cash and Marketable Securities
    $768 millionup $90 million sequentially
    end of Q4 FY25

    Strong balance sheet.

    CapEx
    $8 million
    Q4 FY25

    Offsetting cash flow from operations.

    OpEx Growth (excluding M&A and FX)
    roughly 13%
    FY25

    With investments in Fit for Growth journey.

    OpEx Increase from Merit and Compensation Inflation
    about 5 percentage points
    FY25

    Of the total OpEx increase.

    Gene Therapy Platform Headwind
    2-point
    FY26

    Impact on organic revenue growth guidance. Creates a 3-point headwind for the Filtration franchise.

    Tariff Surcharges Headwind
    approximately 50 basis points
    FY26

    Included in guidance, represents several million dollars of tariff surcharges. Will continue to evaluate.

    Adjusted Other Income
    $18 millionslightly lower than 2025
    FY26

    Assumed due to lower interest rates.

    SoloVPE PLUS Upgraded Units
    less than 100 units
    Q3-Q4 FY25

    Out of an installed base of 1,500 to 2,000 units, indicating the early stage of the upgrade cycle.

    SoloVPE Installed Base
    1,500 to 2,000 units
    current

    Potential for upgrade cycle.

    FlowVPX Adoption Rate
    25%
    last 1 year

    Of every system sold includes the FlowVPX technology.

    Services as % of Total Sales
    approximately 6%
    FY25

    Below industry benchmark, with an ambition to reach 10% in a few years.

    Services Attachment Rate (Analytics)
    above 50%
    current

    Higher than for larger scale equipment, indicating an area of focus for improvement.

    China Revenue as % of Total Revenue
    approximately 2% to 3%
    FY25

    Used to be about high single digit during COVID.

    Industry KPIs

    9
    MetricValueDetails
    Revenue EPS guidanceFY26 Revenue: $810M-$840M; FY26 Adjusted EPS: $1.93-$2.01USD
    China revenue exposureapproximately 2% to 3%%
    Pricing price realization—
    M a contribution synergiesapproximately 1 pointpoint
    Segment organic revenue growth—
    Bioprocessing orders book to bill—
    Reshoring US manufacturing tailwind—
    Instruments vs consumables services mix—
    Organic core revenue growth by end market14%%

    Product announcements

    5
    ProductTypeDetails
    SoloVPE PLUSlaunch
    ProConnex MixOnelaunch
    AVIPure Resinslaunch
    New Catalog Resins (Proteins)roadmap
    Mid-IR Technologyroadmap

    Deals & partnerships

    3
    908 DevicesAcquisition of 908 Devices' bioprocessing portfolio.

    Acquired in March 2025, now part of Repligen's rebranded PATsmart portfolio. Cross-trained and merged upstream and downstream analytics teams, resulting in a growing funnel of opportunities.

    TanttiIntegration of Tantti.

    Made progress on the integration of Tantti.

    NovasignStrategic partnership and minority investment to develop and integrate machine learning and modeling workflow into Repligen filtration systems.

    Announced in July 2025. Investment in Novasign aims to scale and expand their operations, furthering Repligen's digitization efforts and highlighting minority investments as a capital allocation avenue.

    Risks & headwinds

    6
    Gene Therapy Platform HeadwindFY26

    2-point headwind on 2026 organic revenue growth; 3-point headwind for Filtration franchise.

    FDA Policy Uncertainty2026

    Near-term uncertainty

    Biopharma Strategic Response to MFN2026

    Near-term uncertainty, potential for delay on specific CapEx spending decisions.

    Tariff SurchargesFY26

    Slightly higher impact on revenue and margin than 2025; approximately 50 basis points headwind on gross margin.

    Mitigation: Evaluating implications of recent Supreme Court ruling; administration's alternatives to current regime expected to be a push or slightly better.

    Muted Capital Equipment Demand2025-2026

    CapEx sales flat YoY in 2025, market down significantly (high teens). Expecting somewhat flat sales for downstream systems in 2026.

    Mitigation: Hoping for better macro environment and acceleration of onshoring projects towards mid-year with potential grants.

    Lower Interest IncomeQ4 FY25, FY26

    $2 million lower in Q4 FY25; assumed $18 million for FY26 (slightly lower than 2025).

    What to watch in Q1 FY26

    5

    Conversion of high-probability funnel opportunities

    2026
    Currenthighest level ever
    TargetTranslation into orders and sales

    Why it matters

    Indicates underlying demand strength and potential for upside to guidance.

    I mean we have a very strong funnel of opportunity. And as you know🎣, we're tracking that very specifically, particularly the funnel with high probability above 50%. This is at the highest level ever and significantly higher than a year ago.

    Q&A highlights

    5

    Seeking clarification on the factors influencing the low and high ends of the FY26 guidance, particularly regarding FDA policy, MFN impact, funnel opportunities, and tariffs.

    Tariffs have a minimal impact (<1% of sales), and onshoring opportunities are deferred to 2027. The high-probability funnel is at an all-time high. Key uncertainties include biopharma's digestion of MFN deals potentially delaying CapEx decisions and the slow pace of FDA approvals for biologics in early 2026, which could shift guidance.

    “I mean we have a very strong funnel of opportunity. And as you know, we're tracking that very specifically, particularly the funnel with high probability above 50%. This is at the highest level ever and significantly higher than a year ago.”

    asked by Matthew Larew · answered by Olivier Loeillot

    2 min read6 chapters

    Detailed Narrative

    01

    Strong FY25 Performance and Strategic Execution

    Repligen delivered a robust 16% reported and organic non-COVID growth in FY25, surpassing the high end of its initial guidance. This performance was attributed to broad momentum across its diverse portfolio, customer base, and geographies. The company successfully executed on five strategic priorities, including accelerating growth, driving operating leverage, fostering innovation, pursuing M&A, and enhancing operational fitness, setting a strong foundation for future expansion.

    02

    Portfolio Diversity and Growth Drivers

    The company's diverse product portfolio proved to be a key strength, with Proteins and Process Analytics franchises achieving over 30% growth in Q4, and Chromatography growing over 25%. Consumables were a significant growth driver in Q4, increasing by over 20%. The SoloVPE PLUS upgrade cycle is anticipated to be a multi-year opportunity, and new resins developed for the new modality market are gaining considerable traction, contributing to sustained growth.

    03

    Margin Expansion and Strategic Investments

    Repligen expanded its adjusted operating margin by 90 basis points to 13.8% in FY25, or 240 basis points excluding the impact of M&A and foreign exchange. This margin expansion was achieved while making critical investments in legal, finance, IT leadership, AI, and infrastructure. For FY26, the company targets an additional 150 basis points of operating margin expansion, balancing profitability with necessary investments for future scalability.

    04

    M&A and Capital Allocation Strategy

    In FY25, Repligen expanded its portfolio through the acquisition of 908 Devices' bioprocessing assets and a strategic minority investment in Novasign. M&A remains the top capital allocation priority for FY26, with a focus on acquiring differentiated technologies that address customer pain points and offer financial accretion. The company maintains a healthy balance sheet with $768 million in cash and marketable securities to support these strategic initiatives.

    05

    Regional Performance and China Outlook

    North America and Europe each grew approximately 16% in FY25, while Asia Pacific saw 19% growth. China, despite representing a smaller portion of total revenue (2-3% in FY25), showed positive momentum with two consecutive quarters of top-line growth and strong Q4 orders. Repligen is optimistic about China returning to significant growth in FY26 and beyond, driven by increased investment and strategic partnerships in the region.

    06

    Services Growth Opportunity

    Services currently account for approximately 6% of Repligen's total sales, significantly below industry benchmarks. The company identifies this as a substantial growth opportunity, aiming to reach 10% of total sales in the coming years. Efforts are focused on increasing attachment rates for larger-scale equipment, leveraging the high success seen in the analytics franchise, and investing in dedicated commercial resources for service expansion.

    AI-generated summary of the company’s earnings call. Not investment advice.